Physician profile
Mary Setser
NPI 1619302262
$2,441.56
in general payments reported to CMS, 2019-2025
26 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $538 · 2023: $648 · 2024: $538 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $285.71 | 2022-2025 | |
| Lilly USA, LLC | $270.78 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $195.36 | 2021-2024 | Repatha, Otezla, Evenity |
| Pfizer INC. | $182.14 | 2021-2024 | |
| Novo Nordisk INC | $180.29 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.14 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $126.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $120.20 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $119.09 | 2023-2025 | Voquezna |
| Abbvie INC. | $117.09 | 2022-2025 | |
| Corcept Therapeutics | $88.85 | 2021-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.75 | 2023-2024 | Xifaxan |
| Abbott Laboratories | $78.22 | 2024-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $57.40 | 2022-2023 | Injectafer |
| Dexcom, INC. | $57.27 | 2024-2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $52.37 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $42.07 | 2021-2022 | |
| Exact Sciences Corporation | $39.62 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $35.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.25 | 2024 | Airsupra, Farxiga |
| Vertex Pharmaceuticals Incorporated | $22.54 | 2025 | |
| La Jolla Pharmaceutical Company | $18.26 | 2023 | Giapreza |
| Janssen Pharmaceuticals, INC | $17.47 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.14 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.69 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $14.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Setser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.